中国肿瘤外科杂志Issue(6)：364-367,4.DOI:10.3969/j.issn.1674-4136.2015.06.006
EGFR-TKIs 治疗晚期非小细胞肺癌缓慢进展后间插治疗模式的临床观察
Intercalated treatment of advanced non-small cell lung cancer patients with gradual progression after failure of EGFR tyrosine kinase inhibitors therapy：a clinical observation
摘要
Abstract
Objective To observe the PFS (Progression Free Survival) could be extended in advanced NSCLC(non-small cell lung cancer) patients with gradual progression after failure of EGFR tyrosine kinase in-hibitors therapy by intercalated treatment. Methods 24 advanced NSCLC patients from August 2009 to Decem-ber 2014 were collected after gradual progression treated by EGFR-TKIs. All of these patients were accepted in-tercalated treatment of chemotherapy and EGFR-TKIs, in comparison with the PFS of EGFR TKIs treatment to the gradual progression and the PFS of EGFR TKIs treatment to progression of intercalated treatment. Follow-up visit came to end on April 30th , 2015, the median PFS survival was draun accordingly. Results 22 patients could be evaluated on the basis of PFS. The PFS of EGFR TKIs treatment to the gradual progression was 13. 3 months. The PFS of EGFR TKIs treatment to progression of intercalated treatment was 24 months (P < 0. 001). Conclusion The PFS could be signally extended in NSCLC patients with gradual progression after failure of EGFR tyrosine kinase inhibitors therapy by intercalated treatment.关键词
EGFR-TKIs/缓慢进展/间插治疗/非小细胞肺癌/化疗/无进展生存期Key words
EGFR-TKIs/NSCLC gradual progression/Intercalated treatment/NSCLC/Chemothenapy/PFS引用本文复制引用
仲悦娇,刘敏,马蓉,孙小峰,吴平平,周青,朱华云,陈嘉,陈凌翔..EGFR-TKIs 治疗晚期非小细胞肺癌缓慢进展后间插治疗模式的临床观察[J].中国肿瘤外科杂志,2015,(6):364-367,4.基金项目
江苏省肿瘤医院基金(ZM201203) （ZM201203）
